Skip to content
Clinical Research Made Simple

Clinical Research Made Simple

Trusted Resource for Clinical Trials, Protocols & Progress

  • Home
  • Audit Findings
    • General Audit Findings in Clinical Trials
    • Investigator Site-Level Audit Findings
    • Sponsor & CRO-Level Audit Findings
    • Trial Master File (TMF) & eTMF Audit Findings
    • Informed Consent Audit Findings
    • Safety Reporting Audit Findings
    • Data Integrity & EDC Audit Findings
    • GCP Training & Compliance Audit Findings
    • Clinical Trial Supply & IMP Audit Findings
    • Ethics Committee / IRB Audit Findings
    • CAPA & Inspection Readiness Audit Findings
    • Case Studies & Trends in Audit Findings
  • Audits, CAPA & Deviations
    • CRO Audit Oversight
    • CAPA Management in CROs
    • Deviation Handling in CROs
    • Inspection Readiness for CROs
    • Data Integrity & Systems Oversight
    • Training & Quality Culture in CROs
  • SOPs for GCP
    • Global SOPs (Applicable to all Agencies)
    • SOP for IDE/Device
    • FDA — Unique SOPs (United States)
    • EMA — Unique SOPs (European Union)
    • CDSCO/DCGI – Unique SOPs (India)
    • WHO – Unique SOPs
    • ICH – Unique SOPs
    • MHRA — Unique SOPs (United Kingdom)
    • Health Canada — Unique SOPs (Canada)
    • PMDA — Unique SOPs
    • TGA — Unique SOPs
    • NMPA — Unique SOPs
    • ANVISA — Unique SOPs
    • Swiss Medic — Unique SOPs
    • Medsafe/HDEC — Unique SOPs (New Zealand)
  • US Regulatory Submissions
  • Toggle search form

CTMS ↔ eTMF Data Mapping Guide: Fields, Ownership, Audit Trails

Posted on November 6, 2025 digi By digi

CTMS ↔ eTMF Data Mapping Guide: Fields, Ownership, Audit Trails

Published on 22/12/2025

CTMS ↔ eTMF Data Mapping: Field-Level Rules, Ownership, and Audit Trails That Stand Up in FDA/MHRA Inspections

Table of Contents

Toggle
  • Why precise CTMS–eTMF mapping wins inspections: from “two versions of truth” to one stitched record
  • Regulatory mapping: US-first expectations with EU/UK portability
  • Field-by-field mapping blueprint: events, documents, timestamps, owners
  • Decision Matrix: choose ownership, sync, and reconciliation options that scale
  • Make mapping reproducible: models, run logs, and lineage
  • Common pitfalls and fast fixes: from misfiles to version drift
  • Modern realities: decentralized inputs, devices, and privacy
  • Templates & tokens reviewers appreciate
  • FAQs

Why precise CTMS–eTMF mapping wins inspections: from “two versions of truth” to one stitched record

Define the outcome: one story told by two systems

The purpose of a CTMS–eTMF integration is not convenience; it is credibility. In an inspection, assessors expect CTMS operational events (site activation, visits, monitoring outcomes, milestones) to reconcile with evidence filed in the TMF/eTMF. When fields, owners, and timestamps are mapped explicitly—and your team can reproduce numbers with drill-through—live requests resolve in minutes instead of hours.

State your controls once—then cross-reference

Open your mapping specification with a single “Systems & Records” paragraph: electronic records and signatures comply with 21 CFR Part 11 and align to Annex 11; integrations are validated; the audit trail is periodically reviewed; and anomalies route through CAPA with effectiveness checks. Use harmonized language (ICH E6(R3) for oversight, ICH E2B(R3) where safety messaging touches your workflow), keep registry narratives consistent with ClinicalTrials.gov and portable to EU listings (EU-CTR via CTIS), and map privacy to HIPAA with GDPR/UK GDPR notes. Where authoritative anchors help reviewers, embed concise links to the

href="https://www.fda.gov">Food and Drug Administration, the European Medicines Agency, the UK’s MHRA, the ICH, the WHO, Japan’s PMDA, and Australia’s TGA.

Make trust visible: ownership and thresholds

Publish a RACI that assigns which system “owns” each field and which role owns each reconciliation rule. Back the mapping with operational thresholds: “Visit report finalized ≤5 business days after visit; filed-approved in eTMF ≤5 days; skew between CTMS visit date and eTMF report filed-approved date ≤3 days.” Tie metric breaches to escalation with program-level QTLs and risk-based monitoring (RBM) minutes.

Regulatory mapping: US-first expectations with EU/UK portability

US (FDA) angle—what inspectors actually test in the room

During FDA BIMO activity, auditors sample CTMS events and ask for corresponding eTMF artifacts live. They test whether timestamps are contemporaneous, whether signers and owners are clear, and whether the mapping rules are reproducible from your specification. They may pivot from CTMS “monitoring visit occurred” to the eTMF monitoring report, letters, follow-up actions, and evidence of closure—timed with a stopwatch.

See also  TMF Timeliness SLAs & Thresholds: Audit-Ready Evidence

EU/UK (EMA/MHRA) angle—same science, different wrappers

EU/UK review teams emphasize DIA TMF Model structure, sponsor–CRO splits, and site-level currency. If your mapping is authored in ICH language and uses clear ownership and thresholds, it ports with wrapper changes (terminology, role titles) and aligns easily to EU-CTR/CTIS transparency and UK registry postings.

Dimension US (FDA) EU/UK (EMA/MHRA)
Electronic records 21 CFR Part 11 Annex 11
Transparency ClinicalTrials.gov EU-CTR in CTIS; UK registry
Privacy HIPAA GDPR / UK GDPR
Traceability lens CTMS events ↔ eTMF artifacts, live DIA structure, site file currency
Standards language ICH E6/E2B in US narrative ICH vocabulary with EU/UK wrappers

Field-by-field mapping blueprint: events, documents, timestamps, owners

Core event groups and their evidence

Site activation: CTMS owns target/actual activation dates; eTMF owns approvals (IRB/EC, contracts), essential document packets, and activation letters. Reconciliation checks that CTMS “actual activation” occurs after eTMF “activation packet filed-approved.”
Monitoring visits: CTMS owns visit schedule and occurred dates; eTMF owns visit reports and follow-up letters. Reconcile gaps >3 days and require documented reasons (“late filing—site outage,” etc.).
Safety communications: CTMS owns issuance and site acknowledgment milestones; eTMF owns letters, distribution logs, and acknowledgments.

Timestamp rules that eliminate ambiguity

Define start/stop events precisely (e.g., “finalized = last signer completed; filed-approved = eTMF state transition approved”). State how clock skew is handled and what constitutes an exclusion window (sponsor-approved blackout, regulator-imposed hold). Display skew trends on dashboards by site and artifact class.

Owner of record and deputy model

Every mapped element has an accountable owner (sponsor CTMS lead, CRO eTMF manager) and a named deputy. Deputies prevent turnover gaps and keep reconciliation cadence uninterrupted.

  1. List each CTMS event and its eTMF evidence set on a single page.
  2. Write start/stop rules and skew tolerances next to each pair.
  3. Assign owner and deputy per field and per reconciliation rule.
  4. Publish exclusions and approval flow for one-off exceptions.
  5. Enable drill-through from metrics to artifact locations.

Decision Matrix: choose ownership, sync, and reconciliation options that scale

Scenario Ownership Choice Sync Pattern Proof Required Risk if Wrong
Visit scheduling and occurrence CTMS owns schedule/occurred; eTMF owns reports Nightly delta + on-demand Skew ≤3 days; drill-through listings Unexplained gaps; retrieval failures
Regulatory packet (IRB/EC approvals) eTMF owns artifacts; CTMS mirrors status Status mirror only State machine map; sample logs Conflicting states across systems
Safety letters & acknowledgments CTMS owns milestones; eTMF owns documents Event push to document queue Timeliness tables; site ack proof Ethics exposure; site non-currency
Training evidence eTMF owns certificates; CTMS mirrors completion Roster-based sync Roster ↔ artifact cross-check Untrained personnel recorded as active
See also  Investigator Meeting Content Map: Drive Screen Quality Day-1

How to document decisions in the TMF

Maintain a “Mapping Decision Log” with question → option chosen → rationale → evidence anchors (screenshots, listings) → owner → due date → effectiveness result. File under sponsor quality and cross-link to governance minutes.

Make mapping reproducible: models, run logs, and lineage

Specification as a controlled document

Version your mapping spec like an SOP. Include a data dictionary, state transitions (draft→finalized→filed-approved), and error codes. Attach test cases with expected results. Store change history and impact assessments.

Run logs & environment hashes

Every reconciliation run should save a timestamped log and parameter file (date ranges, sites, artifact classes) with environment hashes for rebuilds. Borrow discipline from statistical programming and CDISC lineage (e.g., planned SDTM and ADaM deliverables), even if outputs aren’t yet part of the TMF.

Evidence pack your inspectors can traverse

File a compact “Request → Evidence” diagram showing: inspector request from CTMS; filter to the event; jump to mapped eTMF artifact; open location; capture retrieval time. Include mock timings to prove your live SLA.

  • Systems & Records appendix (validation, Part 11/Annex 11, periodic audit trail review, CAPA routing)
  • Mapping spec (dictionary, state machine, error codes, test cases)
  • Reconciliation run logs (parameters, hashes, rerun steps)
  • Variance lists with owners and closure notes
  • Dashboards with drill-through to artifact locations
  • Governance minutes and effectiveness checks tied to QTLs

Common pitfalls and fast fixes: from misfiles to version drift

Misfiled or misnamed artifacts

Implement short naming rules (StudyID_SiteID_ArtifactType_Version_Date) and folder locks to approved patterns. For backlogs, script batch re-indexing with dry-runs and QC sampling. Track misfile per 1,000 artifacts and show decline post-training.

Version drift between CTMS and eTMF

Allow CTMS to mirror status from eTMF for document states, not own them. Alert when CTMS shows a state transition that lacks a corresponding eTMF artifact ID or “filed-approved” timestamp.

Late filings and missing signatures

Define tiered SLAs and a live retrieval SLA (“10 artifacts in 10 minutes”). For signatures, use e-sign workflows that block “signature after use,” support delegation with auditability, and reconcile site acknowledgments for site-facing updates.

Modern realities: decentralized inputs, devices, and privacy

Decentralized and patient-reported data streams

Where decentralized trial elements (DCT) or patient-reported endpoints (eCOA) generate artifacts (device manuals, training, clarifications), map identity assurance, time sync, and version pins explicitly. Monitor timeliness and completeness at these interfaces with dedicated KPIs until stability is proven.

See also  TMF Health Dashboards That Work: Backlogs, Risk, Actions

Device interfaces and cross-functional dependencies

For connected devices or software components that affect operations, align operational documents with manufacturing/device updates. If process changes introduce risk, reference operational comparability notes so inspectors see awareness and linkage—even if CMC filings sit elsewhere.

Privacy and least-privilege

Document role-based access across both systems. Keep PII/PHI minimized and masked where not required, with audit trails capturing access attempts. Articulate HIPAA mapping and GDPR/UK GDPR portability in the Systems & Records appendix.

Templates & tokens reviewers appreciate

Sample mapping language you can paste

Ownership token: “CTMS owns event dates and operational status; eTMF owns document state and artifact IDs. CTMS mirrors document status via integration; eTMF remains system of record.”

Skew token: “Visit occurred (CTMS) and report filed-approved (eTMF) skew ≤3 days; exceptions require reason code and governance note within 5 business days.”

Drill-through token: “Every KPI tile drills to a listing containing artifact IDs, eTMF locations, owners, timestamps, and links to the audit trail excerpt.”

Quick fixes that change behavior

Pitfall: Two systems, two clocks. Fix: Assign a single clock per event/document and mirror the other.
Pitfall: Dashboards without action. Fix: Add “assign owner,” “due date,” and “comment” to widgets; track recurrence rates.
Pitfall: Orphaned links. Fix: Maintain an Anchor Register; run link-checks before major milestones.

FAQs

Which fields should CTMS own vs eTMF?

CTMS should own operational events and dates (e.g., visit scheduled/occurred, milestones, site activation). eTMF should own document states, artifact IDs, and filed-approved timestamps. CTMS may mirror document status for convenience, but eTMF remains the system of record.

How do we reconcile quickly during inspection?

Use a mapping spec with drill-through dashboards: from CTMS event to mapped eTMF artifact and location in two clicks. Rehearse “10 in 10” retrieval and store stopwatch results. Keep variance lists with owners and closure evidence in the eTMF.

What skew between CTMS and eTMF is acceptable?

Most sponsors adopt ≤3 calendar days between CTMS event date and eTMF filed-approved date for high-volume artifacts. For critical communications (e.g., safety letters, new ICF), targets are tighter and event-specific.

How do we prevent misfiles at scale?

Short naming tokens, folder locks, superuser coaching, targeted QC on high-error sections, and automated checks that flag out-of-pattern placements. Track misfiles per 1,000 artifacts and show sustained reduction after training.

How do decentralized streams change the mapping?

They introduce identity checks, time sync validation, and version pinning at the ingestion point. Treat these as specific risk areas with dedicated KPIs until stability is demonstrated across cycles.

Do we need CDISC alignment in mapping?

While CTMS–eTMF mapping is operational, adopting CDISC lineage expectations helps traceability. Where TMF stores analysis specifications, use consistent terminology with planned SDTM/ADaM outputs to avoid downstream disputes.

Clinical Trial Operations & Data Integrity, TMF & eTMF Tags:(capa), 21 CFR Part 11, ADaM, Annex 11, audit trail, CDISC, ClinicalTrials.gov, comparability, CTIS, CTMS, DCT, eCOA, EU-CTR, FDA BIMO, HIPAA, ICH E2B(R3), ICH E6(R3), QTLs, RBM, SDTM, TMF eTMF

Post navigation

Previous Post: Estimands → Outputs Traceability: Keep the Thread Intact
Next Post: Run Logs & Reproducibility: Scripted Builds, Env Hashes, Params

A professional learning channel built for Pharmaceutical, Clinical, Biotech, and Life Sciences professionals who want to strengthen inspection thinking and make confident quality decisions.

Welcome to GMP Scenarios

Quick Guide – 1

  • Clinical Trial Phases (7)
    • Preclinical Studies (25)
    • Phase 0 (Microdosing Studies) (6)
    • Phase 1 (Safety and Dosage) (66)
    • Phase 2 (Efficacy and Side Effects) (54)
    • Phase 3 (Confirmation and Monitoring) (70)
    • Phase 4 (Post-Marketing Surveillance) (79)
  • Regulatory Guidelines (71)
    • U.S. FDA Regulations (14)
    • CDSCO (India) Guidelines (11)
    • EMA (European Medicines Agency) Guidelines (17)
    • PMDA (Japan) Guidelines (1)
    • MHRA (UK) Guidelines (1)
    • TGA (Australia) Guidelines (1)
    • Health Canada Guidelines (1)
    • WHO Guidelines (1)
    • ICH Guidelines (12)
    • ASEAN Guidelines (11)
  • Country-Specific Clinical Trials (254)
    • Clinical Trials in USA (51)
    • Clinical Trials in China (49)
    • Clinical Trials in EU (51)
    • Clinical Trials in India (51)
    • Clinical Trials in UK (51)
    • Clinical Trials in Canada (1)
  • Clinical Trial Design and Protocol Development (106)
    • Randomized Controlled Trials (RCTs) (11)
    • Adaptive Trial Designs (10)
    • Crossover Trials (10)
    • Parallel Group Designs (11)
    • Factorial Designs (11)
    • Cluster Randomized Trials (11)
    • Single-Arm Trials (10)
    • Open-Label Studies (11)
    • Blinded Studies (Single, Double, Triple) (11)
    • Non-Inferiority and Equivalence Trials (8)
    • Randomization Techniques in Crossover Trials (1)
  • Good Clinical Practice (GCP) and Compliance (78)
    • GCP Training Programs (11)
    • ICH-GCP Compliance (11)
    • GCP Violations and Audit Responses (11)
    • Monitoring Plans (11)
    • Investigator Responsibilities (11)
    • Sponsor Responsibilities (11)
    • Ethics Committee Roles (11)
  • Clinical Research Operations (44)
    • Study Start-Up Activities (9)
    • Site Selection and Initiation (10)
    • Patient Enrollment Strategies (13)
    • Data Collection and Management (10)
    • Monitoring and Auditing (1)
    • Study Close-Out Procedures (0)
  • Site Management and Monitoring (72)
    • Site Feasibility Assessments (20)
    • Site Initiation Visits (10)
    • Routine Monitoring Visits (10)
    • Source Data Verification (12)
    • Site Close-Out Visits (10)
    • Site Performance Metrics (10)
  • Contract Research Organizations (CROs) (55)
    • Full-Service CROs (11)
    • Functional Service Providers (FSPs) (10)
    • Niche/Specialty CROs (11)
    • CRO Selection Criteria (11)
    • CRO Oversight and Management (11)
  • Patient Recruitment and Retention (57)
    • Recruitment Strategies (11)
    • Retention Strategies (11)
    • Patient Engagement Tools (11)
    • Diversity and Inclusion in Trials (11)
    • Use of Social Media for Recruitment (12)
  • Informed Consent and Ethics Committees (54)
    • Informed Consent Process (11)
    • Ethics Committee Submissions (10)
    • Ethical Considerations in Vulnerable Populations (11)
    • Consent in Emergency Research (10)
    • Re-Consent Procedures (11)
  • Decentralized Clinical Trials (DCTs) (55)
    • Remote Patient Monitoring (10)
    • Telemedicine in Trials (11)
    • Home Health Visits (11)
    • Direct-to-Patient Drug Delivery (11)
    • Digital Consent Platforms (11)
  • Clinical Trial Supply and Logistics (55)
    • Investigational Product Management (11)
    • Cold Chain Logistics (10)
    • Supply Chain Risk Management (11)
    • Labeling and Packaging (11)
    • Return and Destruction of Supplies (11)
  • Safety Reporting and Pharmacovigilance (56)
    • Adverse Event Reporting (11)
    • Serious Adverse Event (SAE) Management (11)
    • Safety Signal Detection (11)
    • Risk Management Plans (11)
    • Periodic Safety Update Reports (PSURs) (11)
  • Clinical Data Management (57)
    • Case Report Form (CRF) Design (11)
    • Data Entry and Validation (11)
    • Query Management (11)
    • Database Lock Procedures (11)
    • Data Archiving (12)
  • Biostatistics in Clinical Research (57)
    • Statistical Analysis Plans (11)
    • Sample Size Determination (11)
    • Interim Analysis (11)
    • Survival Analysis (12)
    • Handling Missing Data (11)
  • Real-World Evidence (RWE) and Observational Studies (56)
    • Registry Studies (11)
    • Retrospective Chart Reviews (11)
    • Prospective Cohort Studies (11)
    • Case-Control Studies (11)
    • Use of Electronic Health Records (EHRs) (11)
  • Medical Writing and Study Documentation (58)
    • Protocol Writing (11)
    • Investigator Brochures (11)
    • Clinical Study Reports (CSRs) (11)
    • Manuscript Preparation (11)
    • Regulatory Submission Documents (13)
  • Trial Master File (TMF) Management (57)
    • TMF Structure and Contents (10)
    • Electronic TMF Systems (7)
    • TMF Quality Control (12)
    • Inspection Readiness (12)
    • Archiving Requirements (11)
  • Protocol Amendments and Version Control (45)
    • Amendment Classification (11)
    • Regulatory Submissions of Amendments (11)
    • Communication of Changes to Sites (11)
    • Version Control Systems (11)
  • Data Integrity and ALCOA+ Principles (46)
    • Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA) (12)
    • Complete, Consistent, Enduring, and Available (ALCOA+) (10)
    • Data Governance Policies (12)
    • Audit Trails (11)
  • Investigator and Site Training (44)
    • Investigator Meetings (11)
    • Site Staff Training Programs (11)
    • Training Documentation (11)
    • Continuing Education Requirements (10)
  • Budgeting and Financial Management (40)
    • Budget Development (10)
    • Site Payment Management (10)
    • Financial Forecasting (10)
    • Cost Tracking and Reporting (10)
  • AI, Big Data, and Technology in Clinical Trials (41)
    • AI in Patient Recruitment (10)
    • Machine Learning for Data Analysis (10)
    • Blockchain for Data Security (10)
    • Wearable Devices and Sensors (11)
  • Career in Clinical Research (52)
    • Clinical Research Coordinator (CRC) Roles (11)
    • Clinical Research Associate (CRA) Roles (10)
    • Data Manager Careers (10)
    • Biostatistician Roles (10)
    • Regulatory Affairs Careers (11)
  • Clinical Trial Registries and Result Disclosure (40)
    • ClinicalTrials.gov Registration (9)
    • EudraCT Registration (10)
    • Results Posting Requirements (10)
    • Transparency Initiatives (11)

Quick Guide – 2

  • Clinical Trial Operations & Data Integrity (31)
    • TMF & eTMF (10)
    • Study Operations & Enrollment (10)
    • Biostats, CDISC & Traceability (11)
  • Clinical Trial Operations & Compliance (54)
    • Clinical Trial Logistics (30)
    • TMF / eTMF Management (6)
    • Clinical Trial Phases & Design (6)
    • Regulatory Submissions (CTD/eCTD) (6)
    • Vendor Oversight & CRO Compliance (6)
  • Quality Assurance and Audit Management (40)
    • Internal Audits (10)
    • External Audits (10)
    • Audit Preparation (10)
    • Corrective and Preventive Actions (CAPA) (10)
  • Risk-Based Monitoring (RBM) (40)
    • Risk Assessment Tools (10)
    • Centralized Monitoring Techniques (10)
    • Key Risk Indicators (KRIs) (10)
    • Key Risk Indicators (KRIs) (10)
  • Standard Operating Procedures (SOPs) (39)
    • SOP Development (9)
    • SOP Training (10)
    • SOP Compliance Monitoring (10)
    • SOP Revision Processes (10)
  • Electronic Data Capture (EDC) and eCRFs (40)
    • EDC System Selection (10)
    • eCRF Design (10)
    • Data Validation Rules (10)
    • User Access Management (10)
  • Wearables and Digital Endpoints (35)
    • Integration of Wearable Devices (10)
    • Digital Biomarkers (9)
    • Data Collection and Analysis (7)
    • Regulatory Considerations (9)
  • Blockchain and Data Security in Trials (39)
    • Blockchain Applications in Clinical Research (10)
    • Data Encryption Methods (9)
    • Access Control Mechanisms (11)
    • Compliance with Data Protection Regulations (9)
  • Biomarkers and Companion Diagnostics (39)
    • Biomarker Identification (10)
    • Validation Processes (10)
    • Companion Diagnostic Development (9)
    • Regulatory Approval Pathways (10)
  • Pediatric and Geriatric Clinical Trials (55)
    • Ethical Considerations (11)
    • Age-Specific Protocol Design (22)
    • Dosing and Safety Assessments (11)
    • Recruitment Strategies (11)
  • Oncology Clinical Trials (54)
    • Phase-Specific Oncology Trials (10)
    • Immunotherapy Studies (14)
    • Biomarker-Driven Trials (10)
    • Basket and Umbrella Trials (8)
    • Cancer Vaccines (12)
  • Vaccine Clinical Trials (40)
    • Phase I–IV Vaccine Trials (10)
    • Immunogenicity Assessments (10)
    • Cold Chain Requirements (10)
    • Post-Marketing Surveillance (10)
  • Rare and Orphan Disease Trials (186)
    • Patient Recruitment Challenges (31)
    • Regulatory Incentives (10)
    • Adaptive Trial Designs (10)
    • Natural History Studies (10)
    • Regulatory Frameworks (22)
    • Trial Design & Methodology (22)
    • Operational Challenges (21)
    • Ethics & Patient Engagement (20)
    • Data & Technology (20)
    • Case Studies & Breakthroughs (20)
  • Bioavailability and Bioequivalence Studies (BA/BE) (41)
    • Study Design Considerations (11)
    • Analytical Method Validation (10)
    • Statistical Analysis Requirements (10)
    • Regulatory Submission (10)
  • Regulatory Submissions and Approvals (73)
    • IND (Investigational New Drug) Submissions (10)
    • CTA (Clinical Trial Application) (10)
    • NDA/BLA/MAA Filings (10)
    • ANDA for Generics (10)
    • eCTD Submission Process (2)
    • Pre-Submission Meetings (FDA Type A/B/C) (10)
    • Regulatory Query Response Handling (10)
    • Post-Approval Commitments (11)
  • Clinical Trial Transparency and Ethics (60)
    • Trial Disclosure Obligations (10)
    • Result Publication Requirements (10)
    • Ethical Review Standards (10)
    • Open Access Data Sharing (10)
    • Informed Consent Disclosure (10)
    • Ethical Dilemmas in Global Research (10)
  • Protocol Deviation and CAPA Management (50)
    • Major vs Minor Deviations (10)
    • Root Cause Analysis (9)
    • CAPA Documentation (9)
    • Preventive Action Planning (1)
    • Monitoring and Training Based on Deviations (10)
    • Deviation Logs and Tracking Tools (11)
  • Audit Trails and Inspection Readiness (59)
    • TMF and eTMF Audit Trails (10)
    • Audit Trail Reviews in EDC (10)
    • Inspection Preparation Checklists (10)
    • Regulatory Inspection Types (Routine, For-Cause) (10)
    • Responding to Audit Observations (9)
    • Mock Inspections and Readiness Drills (10)
  • Study Feasibility and Site Selection (68)
    • Feasibility Questionnaire Design (10)
    • Site Capability Assessment (11)
    • Historical Performance Review (17)
    • Geographic and Demographic Considerations (10)
    • PI (Principal Investigator) Experience Evaluation (10)
    • Site Activation Planning (10)
  • Outsourcing and Vendor Management (65)
    • Vendor Qualification Process (12)
    • Due Diligence and Risk Assessment (11)
    • Vendor Contract Management (12)
    • KPIs for Vendor Performance (10)
    • Vendor Oversight and Audits (10)
    • Communication and Escalation Plans (10)
  • Remote Monitoring and Virtual Visits (64)
    • Centralized Monitoring Techniques (12)
    • Source Data Review Remotely (12)
    • Virtual Site Visits Protocols (11)
    • eConsent and Remote Data Collection (10)
    • Hybrid Monitoring Models (10)
    • Remote Site Training (9)
  • Laboratory and Sample Management (77)
    • Sample Collection SOPs (10)
    • Sample Labeling and Transport (10)
    • Chain of Custody Documentation (11)
    • Bioanalytical Testing and Storage (15)
    • Central vs Local Labs (11)
    • Laboratory Data Reconciliation (20)
  • Adverse Event Reporting and Management (63)
    • AE vs SAE Differentiation (10)
    • Expedited Reporting Timelines (11)
    • MedDRA Coding of Events (11)
    • AE Data Collection in eCRFs (11)
    • Causality and Severity Assessments (10)
    • Regulatory Reporting Requirements (CIOMS, SUSARs) (10)
  • Interim Analysis and Trial Termination (60)
    • Data Monitoring Committees (DMC) (10)
    • Pre-Specified Stopping Rules (10)
    • Statistical Thresholds for Early Stopping (10)
    • Adaptive Modifications Based on Interim Data (10)
    • Unblinding Protocols (10)
    • Reporting of Early Termination to Regulators (10)

Recent Posts

  • Test
  • Comprehensive Guide to Dental Health Care with Braces
  • Understanding Dental Health Care: Managing Implants Cost Effectively
  • Invisalign Alternatives: Practical Dental Health Care Solutions
  • Practical Guide to Dental Health Care: Managing Braces Effectively

Copyright © 2026 Clinical Research Made Simple.

Powered by PressBook WordPress theme